393 Shares in Axonics, Inc. (NASDAQ:AXNX) Acquired by Wipfli Financial Advisors LLC

Wipfli Financial Advisors LLC acquired a new position in Axonics, Inc. (NASDAQ:AXNXGet Rating) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 393 shares of the company’s stock, valued at approximately $28,000.

A number of other large investors also recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its stake in Axonics by 14.1% in the second quarter. Nisa Investment Advisors LLC now owns 1,620 shares of the company’s stock worth $92,000 after buying an additional 200 shares in the last quarter. LPL Financial LLC raised its stake in Axonics by 6.3% in the second quarter. LPL Financial LLC now owns 3,727 shares of the company’s stock worth $211,000 after buying an additional 222 shares in the last quarter. Captrust Financial Advisors raised its stake in Axonics by 34.1% in the second quarter. Captrust Financial Advisors now owns 947 shares of the company’s stock worth $54,000 after buying an additional 241 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Axonics by 6.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 5,207 shares of the company’s stock worth $326,000 after purchasing an additional 326 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Axonics by 3.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 10,866 shares of the company’s stock worth $616,000 after purchasing an additional 326 shares in the last quarter. Institutional investors own 97.49% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AXNX. Morgan Stanley reduced their price target on Axonics from $92.00 to $76.00 and set an “overweight” rating on the stock in a research report on Friday, January 6th. TheStreet raised Axonics from a “d+” rating to a “c” rating in a research report on Monday, October 31st. Truist Financial reduced their price target on Axonics from $90.00 to $82.00 and set a “buy” rating on the stock in a research report on Tuesday, December 20th. Royal Bank of Canada started coverage on Axonics in a research report on Friday, October 21st. They set an “outperform” rating and a $85.00 price target on the stock. Finally, Piper Sandler boosted their price objective on shares of Axonics from $82.00 to $84.00 and gave the company an “overweight” rating in a report on Wednesday, October 5th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Axonics currently has an average rating of “Moderate Buy” and a consensus target price of $78.11.

Insider Buying and Selling at Axonics

In other Axonics news, CEO Raymond W. Cohen sold 40,736 shares of the company’s stock in a transaction on Friday, January 13th. The shares were sold at an average price of $65.94, for a total value of $2,686,131.84. Following the sale, the chief executive officer now directly owns 108,899 shares of the company’s stock, valued at $7,180,800.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Axonics news, insider Alfred J. Ford, Jr. sold 36,015 shares of the company’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $66.40, for a total value of $2,391,396.00. Following the completion of the transaction, the insider now owns 36,773 shares in the company, valued at $2,441,727.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Raymond W. Cohen sold 40,736 shares of the company’s stock in a transaction dated Friday, January 13th. The stock was sold at an average price of $65.94, for a total transaction of $2,686,131.84. Following the completion of the transaction, the chief executive officer now owns 108,899 shares of the company’s stock, valued at approximately $7,180,800.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 108,966 shares of company stock valued at $7,247,046. 2.31% of the stock is owned by insiders.

Axonics Stock Performance

NASDAQ:AXNX opened at $62.02 on Friday. Axonics, Inc. has a one year low of $38.41 and a one year high of $79.92. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -37.59 and a beta of 0.43. The firm’s fifty day moving average is $63.46 and its two-hundred day moving average is $67.07.

Axonics (NASDAQ:AXNXGet Rating) last posted its quarterly earnings results on Monday, October 31st. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.13. Axonics had a negative net margin of 31.35% and a negative return on equity of 15.63%. The company had revenue of $70.38 million for the quarter, compared to analyst estimates of $62.98 million. During the same period in the prior year, the company earned ($0.38) earnings per share. The firm’s revenue was up 50.0% on a year-over-year basis. As a group, equities research analysts predict that Axonics, Inc. will post -1.59 earnings per share for the current fiscal year.

Axonics Profile

(Get Rating)

Axonics, Inc is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women.

Featured Articles

Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics, Inc. (NASDAQ:AXNXGet Rating).

Institutional Ownership by Quarter for Axonics (NASDAQ:AXNX)

Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.